XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial by Maggie J. Phillips, Olatunji B. Alese, Natalie K. Horvat, Emily Greene, Olumide B. Gbolahan, Kathleen Coleman, Deon B. Doxie, Vaunita Parihar, Zaid K. Mahdi, Ashley McCook-Veal, Jeffrey M. Switchenko, Maria Diab, Cameron J. Herting, Chrystal M. Paulos, Bassel F. El-Rayes, Gregory B. Lesinski

Get full text